Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Community Healthcare MIC team would be excited to hear from practicing healthcare professionals working in community settings who are interested to become involved in our work.

  • Have you identified a particular area of diagnostic clinical need in your context of work or a shortfall in an existing clinical pathway which could be addressed through the deployment of a current or novel technology?
  • Do you have any ideas for new diagnostic tests which we could develop and evaluate in collaboration?
  • Would you be willing to test out exciting new validated technologies in your clinical setting?

Please contact Dr Philip Turner, the Manager of the NIHR Community Healthcare MIC, if you would like discuss the work of the MIC further or if you would like to become involved.

Latest news

Call for industry challenges in tackling antimicrobial resistance

Call for industry's challenges in tackling antimicrobial resistance

Host a roundtable discussion with leading academics to discuss your challenges in developing vaccines, antimicrobials or AMR-relevant point-of-care diagnostics and medical technologies

Are diagnostic tests cost effective modified assessment checklist produced

Are diagnostic tests cost-effective? Modified assessment checklist produced

A diagnostic test-specific checklist to assess decision modelling has been developed and piloted.

Point of care flu tests dont lower antibiotic prescribing study finds

Point-of-care flu tests don't lower antibiotic prescribing, study finds

Tests also have no effect on admission or return visits, finds research published in Clinical Infectious Diseases.

Upcoming events:

Academic Industry Meeting Day (AIMday): Antimicrobial Resistance

Thursday, 04 July 2019

Helping to answer the most pressing challenges in antimicrobial resistance, as identified by UK bioscience companies.